

P24071.A01



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Yong Sik YOUN et al.

Appln. No : 10/642,754

Filed : August 19, 2003

For : ORGANIC ACID SALT OF AMLODPINE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir :

In accordance with the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants hereby bring the following information to the attention of the Examiner in charge of the above-identified application, which includes information cited and discussed in the specification.

EP 0 089 167, which is cited and discussed in the specification beginning on page 1, line 20;

U.S. Patent No. 6,291,490, which is cited and discussed in the specification beginning on page 2, line 2;

U.S. Patent No. 4,879,303, which is cited and discussed in the specification beginning on page 2, line 6;

P24071.A01

KR 95-7228, which is a family member of KR 1989-3375 which is cited and discussed in the specification beginning on page 2, line 6, and is accompanied by family member U.S. Patent No. 4,879,303; and

WO 99/52873, which is cited and discussed in the specification beginning on page 2, line 24;

U.S. Patent No. 4,572,909, which is a family member of KR 87-809, which is cited and discussed in the specification beginning on page 7, line 21.

Applicants also bring to the attention of the Examiner:

KR-1991-2145, accompanied by family member U.S. Patent No. 4,758,569.

Copies of the above-noted documents are enclosed together with a duly completed Form PTO-1449. The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the Form PTO-1449. Applicants respectfully request that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Applicants also bring to the Examiner's attention the following copending and commonly assigned patent applications:

U.S. Patent Application No. 10/628,209 to Seong Hwan CHO et al., entitled "Organic Acid Salt of Amlodipine", filed on July 29, 2003;

P24071.A01

U.S. Patent Application No. 10/628,268 to Seong Hwan CHO et al., entitled "Organic Acid Salt of Amlodipine", filed on July 29, 2003; and


U.S. Patent Application No. 10/628,210 to Seong Hwan CHO et al., entitled "Organic Acid Salt of Amlodipine", filed on July 29, 2003.

In accordance with 37 C.F.R. §1.98(a)(2)(iii), copies of the above-mentioned applications are attached hereto. However, the Examiner is also requested to review the file wrapper of these U.S. patent applications at the U.S. Patent and Trademark Office and the references of record, if any, cited therein. In this regard, the applications are not listed on the form PTO-1449 because they are not publications.

In accordance with 37 C.F.R. § 1.97(b)(1), this Information Disclosure Statement is filed within three months of the filing date of the application. Accordingly, no fees are required.

Should there be any questions, the Examiner is invited to contact the undersigned at the below listed telephone number.

Respectfully submitted,
Yong Sik YOUN et al.


Bruce H. Bernstein
Reg. No. 29,027

October 28, 2003
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.